Cytek Biosciences, Inc. · NASDAQ:CTKB
Cytek Biosciences — TD Cowen 46th Annual Healthcare Conference 2026
11 slides from Cytek Biosciences's conference presentation, Mar 4, 2026
Slide 1: Investor Presentation: TD Cowen 46th Annual Healthcare Conference
Investor Presentation TD Cowen 46th Annual Healthcare Conference March 4, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s future financial performance; Cytek’s business and operational strategies; the fore
Slide 3: Empowering scientific communities with leading cell analysis tools
Empowering scientific communities with leading cell analysis tools 3
Slide 4: Cytek 2025 at a Glance
Cytek 2025 at a Glance (1) Broad Customer Base Validated Technology Platform & Global Presence Strong Financial Profile 3,664 2,950 $201.5M Units Placed Customers 2025 Total Revenue >3,500 76 $261.5M Cytek FSP Peer- Countries Cash & Marketable reviewed Publications Securities 1. All metrics are for
Slide 5: Global Scale and Reach with Diversified Revenue Mix
Global Scale and Reach with Diversified Revenue Mix (1) APAC & 25% % Revenue by Industry USA 47% EMEA(2) 28% ROW (3) Academic and Government-Owned 42% Institutions 58% Pharma and Biotech, Distributors and CROs Seattle Amsterdam Fremont (Headquarters) Wuxi Bethesda Tokyo San Diego Shanghai Singapore
Slide 6: Flow Cytometry: An Essential Tool in Many Diverse Applications
Flow Cytometry: An Essential Tool in Many Diverse Applications Flow cytometry is a must-have capability underpinning key Broad Applicability decisions for cell-based experiments, production runs, and clinical workflows. Cell + Gene Therapies Drug Discovery Core Labs, CROs, and cell-therapy manufactu
Slide 7: Large and Growing Global Cell Analysis Market Addressable by Flow Cytometry
Large and Growing Global Cell Analysis Market Addressable by Flow Cytometry (1) $5.1B 2025 TAM (2) 8.8% Global CAGR 2025-2032 $9.2B 2032 Forecasted TAM 1. The Market Reports (2025); https://www.themarketreports.com 2. TAM = Total Addressable Market 7
Slide 8: Comprehensive Portfolio of Best-in-Class Cell Analysis Tools
Instruments Applications Bioinformatics Clinical Comprehensive Portfolio of Best-in-Class Cell Analysis Tools Aurora Evo Cytek Aurora Aurora Cell Sorter Northern Lights Guava Muse Micro Amnis Reagents Cytek Cloud Services 8
Slide 9: Our Strategic Business Pillars
Our Strategic Business Pillars Instruments Applications Bioinformatics Clinical (1) Performance Reagents Cytek Cloud Regulatory Intelligence Enabler Analysis / AI LDT Harmonization Flexibility Optimization Menu Driven Reliability Functionality Management AI Cost Effective Recurring Revenue Exchanges
Slide 10: Growth Drivers
Growth in Growth in Flow Innovative installed base Reagents driven cytometry new products to drive Service by expanding market growth 2026 growth market share Growth Drivers Conventional Cytek Cloud to Clinical flow cytometer improve workflows expansion in replacement cycle and utilization EMEA and
Slide 11: Thank You
e - TRANSCEND THE CONVENTIONAL ‘Thank You
Cytek Biosciences — TD Cowen 46th Annual Healthcare Conference 2026 on 6ix